Pacira | PCRX - Operating Profit


Pacira reported $13.15M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Astellas Pharma JPY 134.54B 30.13B Dec/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 5.59B 1.81B Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Supernus Pharmaceuticals USD -60.18M 72.32M Sep/2025
Teva Pharmaceutical Industries USD 487M 581M Dec/2025
Xeris Pharmaceuticals USD 6.73M 2.25M Sep/2025
Zoetis USD 936M 63M Sep/2025